While the cancer treatments differed based on their diagnosis and responses, both patients had confirmed CCR5-tropic virus before transplant and did not experience HIV rebound after transplant.11 The London patient was noted to have cytomegalovirus (CMV) and Epstein-Barr virus reactivation 85 days after transplant requiring treatment.11 Notably, there were differences in the immune cell composition after transplant, the most significant being the lack of CCR5+ cluster of differentiation (CD)4 and CD8+ T cells. The gene discussed is CCR5; the disease is cancer.